a public good project by the
Synthesis
Company
of California

© 2026

Harpreet Wasan | doi.page

0 works0 citations0 h-index

Harpreet Wasan

Hammersmith Hospital(GB)Imperial College London(GB)

Publications by Year

Research Areas

Colorectal Cancer Treatments and Studies, Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Cholangiocarcinoma and Gallbladder Cancer Studies, Hepatocellular Carcinoma Treatment and Prognosis

Most-Cited Works

→ Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer(2010)4,329 cited
→ ESMO consensus guidelines for the management of patients with metastatic colorectal cancer(2016)3,389 cited
→ Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial(2017)1,902 cited
→ Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer(2019)1,423 cited
→ Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study(2019)1,194 cited
→ Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update(2012)786 cited

→ Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial(2021)725 cited

→ Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document(2002)643 cited

→ Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study(2021)518 cited

Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.(1993)